We are a revolutionary biotherapeutics company and our mission is to revolutionize patient care with therapies that are more effective, safer and allow for easier routes of administration than current options. 

How?

By advancing therapies that restore immune homeostasis, targeting the immune system upstream. They offer a unique mechanism through impact on both the regulatory and effector arms. On the regulatory side, they upregulate T and B regulatory cells. On the effector side, they downregulate effector T cells. This upstream, disease-agnostic and dual action approach results in a rapid and prolonged effect without broad immune suppression. They also have potential to offer dosing optionality through subcutaneous and sublingual routes, based on preclinical research, offering a highly competitive profile with potential to disrupt the current treatment landscape as potential first line therapies.

Why?

Existing therapies for allergic and autoimmune diseases address the problem downstream, once the inflammation has occurred. They only address limited aspects of the immune response with most failing to engage the regulatory component. As a result, these treatments require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.